JP2007516696A - ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含んでなる組成物およびその使用法 - Google Patents

ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含んでなる組成物およびその使用法 Download PDF

Info

Publication number
JP2007516696A
JP2007516696A JP2006533791A JP2006533791A JP2007516696A JP 2007516696 A JP2007516696 A JP 2007516696A JP 2006533791 A JP2006533791 A JP 2006533791A JP 2006533791 A JP2006533791 A JP 2006533791A JP 2007516696 A JP2007516696 A JP 2007516696A
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
acid molecule
sequence
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516696A5 (enExample
Inventor
ウェイナー，デイヴィッド・ビー
クッツラー，ミッチェル
チョー，アンドリュー・ケイ
ヤン，ジョー−スン
ボイアー，ジーン・ディー
Original Assignee
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア filed Critical ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア
Publication of JP2007516696A publication Critical patent/JP2007516696A/ja
Publication of JP2007516696A5 publication Critical patent/JP2007516696A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006533791A 2003-06-13 2004-06-14 ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含んでなる組成物およびその使用法 Pending JP2007516696A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47821003P 2003-06-13 2003-06-13
US47820503P 2003-06-13 2003-06-13
PCT/US2004/018962 WO2005000235A2 (en) 2003-06-13 2004-06-14 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012029973A Division JP5623444B2 (ja) 2003-06-13 2012-02-14 ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含む組成物およびその使用法

Publications (2)

Publication Number Publication Date
JP2007516696A true JP2007516696A (ja) 2007-06-28
JP2007516696A5 JP2007516696A5 (enExample) 2012-04-05

Family

ID=33555491

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006533791A Pending JP2007516696A (ja) 2003-06-13 2004-06-14 ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含んでなる組成物およびその使用法
JP2012029973A Expired - Fee Related JP5623444B2 (ja) 2003-06-13 2012-02-14 ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含む組成物およびその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012029973A Expired - Fee Related JP5623444B2 (ja) 2003-06-13 2012-02-14 ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含む組成物およびその使用法

Country Status (12)

Country Link
US (2) US8173786B2 (enExample)
EP (2) EP1638987B1 (enExample)
JP (2) JP2007516696A (enExample)
KR (2) KR101225473B1 (enExample)
CN (1) CN1832956B (enExample)
AU (2) AU2004251070B2 (enExample)
BR (1) BRPI0411363A (enExample)
CA (1) CA2529145C (enExample)
IL (1) IL172496A (enExample)
MX (1) MXPA05013526A (enExample)
NZ (2) NZ570709A (enExample)
WO (1) WO2005000235A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518599A (ja) * 2010-02-08 2013-05-23 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Ｒａｎｔｅｓをコードする核酸分子、ならびにこれを含む組成物およびこれを用いる方法
JP2015501656A (ja) * 2011-12-12 2015-01-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
JP2015527297A (ja) * 2012-04-12 2015-09-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2023510112A (ja) * 2019-12-19 2023-03-13 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー アフリカ豚熱ウイルスに対するワクチン、およびそれを使用する方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
DK1976871T3 (da) * 2006-01-13 2011-12-12 Univ Pennsylvania Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf
KR101710981B1 (ko) 2006-07-28 2017-02-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US10426827B1 (en) * 2006-11-06 2019-10-01 Microvax, Llc Dengue hemorrhagic fever virus vaccine
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
AU2009231598B2 (en) * 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
WO2009124312A2 (en) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2011032179A1 (en) 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
KR101942372B1 (ko) * 2011-02-11 2019-04-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 B형 간염 바이러스 코어 단백질을 암호화하는 핵산 분자 및 이를 포함하는 백신
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP3511337A1 (en) 2012-04-10 2019-07-17 The Trustees of The University of Pennsylvania Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same
KR102238226B1 (ko) * 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
US10166288B2 (en) * 2014-10-01 2019-01-01 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
KR20180096592A (ko) * 2015-10-22 2018-08-29 모더나티엑스, 인크. 호흡기 세포융합 바이러스 백신
EA201892124A1 (ru) 2016-12-02 2019-04-30 Дэвид Б. Уэйнер Днк-конструкции антител и способы их применения
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
KR20240128814A (ko) 2017-01-10 2024-08-27 프레시전 인코포레이티드 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
BR112020010499A2 (pt) 2017-12-13 2020-11-24 Inovio Pharmaceuticals, Inc. vacinas de câncer de alvo de mesotelina e usos das mesmas
CN111741772A (zh) 2017-12-13 2020-10-02 艾诺奥医药品有限公司 靶向muc16的癌症疫苗和其用途
EP3723798A4 (en) 2017-12-13 2021-11-17 Inovio Pharmaceuticals, Inc. CANCER VACCINES TARGETING BORIS AND RELATED USES
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
US12064481B2 (en) * 2020-11-02 2024-08-20 Drexel University Compositions and methods employing adenosine deaminase-1 (ADA-1) as an adjuvant
WO2022109133A1 (en) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Oncolytic immunotherapy by tumor micro-environment remodeling
WO2022232375A1 (en) * 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526241A (ja) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
WO2002029088A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2157994A (en) 1937-11-08 1939-05-09 Kelsey Hayes Wheel Co Brake mechanism
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) * 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) * 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
ES2070997T3 (es) 1989-12-04 1995-06-16 Akzo Nobel Nv Virus de herpes recombinante de pavos y vacunas vector vivas derivadas de los mismos.
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
PT681483E (pt) 1993-01-26 2005-11-30 Wyeth Corp Composicoes e metodos para distribuicao de material genetico
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) * 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) * 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
EP1950226A3 (en) * 1995-08-01 2010-08-11 F. Hoffmann-La Roche AG An antibody against a receptor for human interleukin - 12 and its use
WO1998017799A1 (en) * 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
WO1999016466A2 (en) * 1997-09-29 1999-04-08 Beth Israel Deaconess Medical Center Vaccine compositions and methods of enhancing vaccine efficacy
CA2320431A1 (en) * 1998-02-11 1999-08-19 Maxygen, Inc. Targeting of genetic vaccine vectors
US7560105B1 (en) * 1999-10-04 2009-07-14 Leids Universitair Medisch Centrum Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses
DE60130206T2 (de) * 2000-05-11 2008-05-29 Baylor Research Institute, Dallas Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
IL160358A0 (en) 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
WO2004000217A2 (en) * 2002-06-20 2003-12-31 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526241A (ja) * 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
WO2002029088A2 (en) * 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Highly expressible genes

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
JPN6010034234; Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１５８，　Ｎｏ．１, 1997, ｐｐ．２５５-２６２ *
JPN6010034235; Ｊ．　Ｌｅｕｋｏｃ．　Ｂｉｏｌ． Ｖｏｌ．６９，　Ｎｏ．４, 2001, ｐｐ．５３１-５３７ *
JPN6010034236; Ｊ．　Ｉｎｆｅｃｔ．　Ｄｉｓ． Ｖｏｌ．１８４，　Ｎｏ．７, 2001, ｐｐ．８０９-８１６ *
JPN6010034237; Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１６５，　Ｎｏ．１１, 2000, ｐｐ．６１３３-６１４１ *
JPN6010034238; Ｂｌｏｏｄ Ｖｏｌ．９９，Ｎｏ．２, 2002, ｐｐ．７２２-７２３ *
JPN6010034240; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ．　ＵＳＡ Ｖｏｌ．１００，　Ｎｏ．６, 20030318, ｐｐ．３３９２-３３９７ *
JPN6010034242; Ｖａｃｃｉｎｅ Ｖｏｌ．１７，　Ｎｏ．７-８, 1999, ｐｐ．８５８-８６６ *
JPN6010034243; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．７６，　Ｎｏ．１, 2002, ｐｐ．２４３-２５０ *
JPN6010034245; Ｅｕｒ．　Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．２８，　Ｎｏ．３, 1998, ｐｐ．１０８９-１１０３ *
JPN6010034248; Ｃａｎｃｅｒ　Ｒｅｓ． Ｖｏｌ．５４，　Ｎｏ．１６, 1994, ｐｐ．４５３９-４５４６ *
JPN6010034251; Ｅｕｒ．　Ｊ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．２７，　Ｎｏ．５, 1997, ｐｐ．１０４９-１０５４ *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518599A (ja) * 2010-02-08 2013-05-23 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Ｒａｎｔｅｓをコードする核酸分子、ならびにこれを含む組成物およびこれを用いる方法
JP2015501656A (ja) * 2011-12-12 2015-01-19 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＲＳＡのＰＢＰ２ａ及びその断片を含むタンパク質、それをコードする核酸、並びにＭＲＳＡ感染を予防する及び治療するための組成物及びそれらの使用
US10980870B2 (en) 2011-12-12 2021-04-20 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA Pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
JP2015527297A (ja) * 2012-04-12 2015-09-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
US10034930B2 (en) 2012-04-12 2018-07-31 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2019006787A (ja) * 2012-04-12 2019-01-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
US10765733B2 (en) 2012-04-12 2020-09-08 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2021001191A (ja) * 2012-04-12 2021-01-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2022078289A (ja) * 2012-04-12 2022-05-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP7164353B2 (ja) 2012-04-12 2022-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
US11723969B2 (en) 2012-04-12 2023-08-15 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
JP2023510112A (ja) * 2019-12-19 2023-03-13 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー アフリカ豚熱ウイルスに対するワクチン、およびそれを使用する方法

Also Published As

Publication number Publication date
AU2012202867A1 (en) 2012-06-07
IL172496A0 (en) 2006-04-10
US20070041941A1 (en) 2007-02-22
AU2004251070A1 (en) 2005-01-06
CN1832956A (zh) 2006-09-13
JP2012110345A (ja) 2012-06-14
KR20110129945A (ko) 2011-12-02
CN1832956B (zh) 2013-11-20
EP2292634A3 (en) 2012-08-08
NZ544077A (en) 2009-01-31
CA2529145C (en) 2017-07-11
EP2292634A2 (en) 2011-03-09
KR101269548B1 (ko) 2013-06-21
BRPI0411363A (pt) 2006-07-25
AU2012202867B2 (en) 2015-01-29
KR101225473B1 (ko) 2013-01-24
EP1638987B1 (en) 2014-11-19
AU2004251070B2 (en) 2012-02-23
NZ570709A (en) 2010-04-30
US8173786B2 (en) 2012-05-08
KR20060030041A (ko) 2006-04-07
JP5623444B2 (ja) 2014-11-12
EP1638987A2 (en) 2006-03-29
US20120276142A1 (en) 2012-11-01
MXPA05013526A (es) 2006-03-09
CA2529145A1 (en) 2005-01-06
IL172496A (en) 2013-02-28
EP1638987A4 (en) 2007-12-26
WO2005000235A2 (en) 2005-01-06
WO2005000235A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
JP5623444B2 (ja) ＩｇＥシグナルペプチドおよび／またはＩＬ−１５をコードする核酸配列およびそれらを含む組成物およびその使用法
JP5801279B2 (ja) コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法
JP5709356B2 (ja) 哺乳動物細胞における発現のためのコドン最適化ＩＬ−１５およびＩＬ−１５Ｒ−α遺伝子
JP2019531090A (ja) 改変されたｖｓｖ−ｇおよびそのワクチン
Bolesta et al. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery
KR101784177B1 (ko) Ｒａｎｔｅｓ를 암호화하는 핵산 분자, 그리고 이를 포함하는 조성물 및 이의 사용 방법
US9278128B2 (en) Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
JP4180826B2 (ja) ＩＬ−１２活性を増加させるＩＬ−１２ｐ４０小単位体突然変異遺伝子及びこれをＤＮＡワクチン免疫増強剤として利用する用途
JP2003526360A6 (ja) ＩＬ−１２活性を増加させるＩＬ−１２ｐ４０小単位体突然変異遺伝子及びこれをＤＮＡワクチン免疫増強剤として利用する用途
Villarreal Alarming immunity: A wake up call for CD8 T cells using genetic adjuvants (IL-33 and ISG15)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100915

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101216

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111014

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120329

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140407

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141117